RudaCure (CEO Yongho Kim), a company specializing in developing treatments for 感觉障碍, was selected as an 仁川 Outstanding Company (Promising Enterprise) at the '2025 仁川 SME Awards and Outstanding Enterprise Certification Ceremony' hosted by 仁川广域市 and organized by 仁川科技园 on the 12th, solidifying its position as a growing company in the 生物制药 development sector.
Founded in 2018, RudaCure has been dedicated to developing 创新药物s that directly and indirectly modulate the TRPV1 (瞫时受体电位香草酸亚型1) 离子通道, offering new treatment options for patients suffering from 感觉障碍 such as 干眼症 and 慢性疼痛.
RudaCure's core technology is a 创新药物 platform that directly and indirectly modulates the TRPV1 离子通道, which regulates pain, 炎症, and temperature sensation. TRPV1 is expressed in 感觉神经 and plays a crucial role in 疼痛信号传导 and 炎症反应. By effectively modulating this channel, RudaCure is developing 创新药物s capable of treating various 感觉障碍. The company's flagship 管线, 干眼症治疗药 'RCI001,' utilizes a mechanism that suppresses 炎症激活 through TRPV1 下游信号调控. Unlike existing treatments, it demonstrates powerful 抗炎和抗氧化效果, showing therapeutic results within 4 weeks along with confirmed increases in 泪液产生. Notably, it has been recognized for overcoming major 副作用 associated with steroid-based treatments, including 眼内压升高, 充血, 出血, and 滴眼时灼热感.
RudaCure signed two 技术转让协议 with 翰林制药 totaling KRW 20 billion in 2021 and 2022, gaining recognition for RCI001's technical excellence. In July 2025, the company achieved FDA Phase 2 IND (研究性新药) approval, with domestic Phase 2 临床试验 planned for 2026. The company is also expanding into the 兽药 market with a KRW 50 billion contract with a French global 兽药 developer.
The 慢性疼痛治疗药 'RCI002' is a dual-target 非麻醉性镇痛药 that simultaneously targets TRPV1 and MOR (Mu阿片受体). In 临床前研究, it demonstrated prolonged 疗效 at concentrations 650 times lower than existing treatments with no 副作用, and is applicable to various 感觉障碍 including 神经性疼痛, 化疗引起的疼痛, and diabetic pain without the 成瘾性 risk of 麻醉性镇痛药.
Behind RudaCure's selection as an outstanding company is not only its excellent technology but also its stable organizational culture. The company has fostered an environment where employees grow together based on its 3C core values: Creativity, Collaboration, and Challenge.
The company offers various financial incentives including stock options, performance bonuses, and long-service allowances, along with flexible work culture such as liberal use of annual leave and casual dress code. It also actively supports employee self-development through education expense subsidies and professional skill enhancement training. As a result, the company maintains a low turnover rate, and employees are moving toward the goal of innovative 药物开发 as One Team, backed by high workplace satisfaction and pride.
RudaCure has consistently been recognized for its organizational excellence, being selected as a Talent-Nurturing SME, Outstanding Job Invention Compensation Company, and Work Innovation Excellence Company in 2022. In 2023, it was selected for the 雇佣劳动部's Strong Small Enterprise program and the 中小企业部' 初创企业 Leap Package support program. In 2024, it was selected for the 宝贝独角兽 200 Development Program, demonstrating its growth potential. The company has raised over KRW 16 billion in total investment through Series A (KRW 6 billion) and Series B (KRW 10 billion), strengthening its 研发 capabilities. Through 技术转让协议 with 翰林制药 and a French 兽药 developer, the company has signed contracts totaling over KRW 70 billion, and is currently discussing 技术转让 for 疼痛治疗药 RCI002 with multiple overseas companies. Continuous revenue growth and 技术转让 achievements further enhance the company's development potential.
CEO Yongho Kim of RudaCure is an expert who has conducted over 15 years of basic medical research on pain and 感觉障碍 as a professor at 嘉泉大学医学院. The company continues to secure globally competitive talent, including the recruitment of Research Director Jiyoon Shin to enhance 药物开发 efficiency using AI.
CEO Kim stated, "This selection as an 仁川 Outstanding Company is a recognition of RudaCure's 研发 capabilities and innovative technology," adding, "Based on our proprietary TRPV1 modulation technology platform, we will provide more effective and safer treatment options for patients suffering from 感觉障碍 and grow into a globally competitive 制药 development company."
RudaCure is targeting an IPO by 2027 in the mid-to-long term. To this end, the company is concentrating all its capabilities on generating 研发 achievements through successful 临床试验 and global 技术转让s. Through its presence at 仁川创业园区 and its 纽约 office in 美国, the company is building a global cooperation network and laying the foundation for growth into a world-class 制药公司.
With its headquarters in 松岛, Yeonsu-gu, 仁川 and its research center in Gasan, Geumcheon-gu, 首尔, RudaCure contributes to local job creation and economic development while establishing itself as a socially responsible company through the adoption of eco-friendly drug manufacturing technology and 可持续经营 practices.
